Magenta Therapeutics Inc
Change company Symbol lookup
Select an option...
MGTA Magenta Therapeutics Inc
PT Pintec Technology Holdings Ltd
CLSH CLS Holdings USA Inc
UN Unilever NV
AWK American Water Works Company Inc
AEG Aegon NV
SBUX Starbucks Corp
PFE Pfizer Inc
CRON Cronos Group Inc
CVSI CV Sciences Inc
Go

Health Care : Biotechnology | Company profile

Magenta Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is developing therapeutics to transform hematopoietic stem cell transplants for patients with immune and blood-based diseases. It maintains a platform with integrated and modular approach, which aims to reboot the blood and immune systems. The Company’s products include MGTA-145, MGTA-456, E478, and G100. The Company also developing a pipeline of small molecules; biologics, including antibody drug conjugates; and a cell therapy, which transplant options for many more patients with autoimmune diseases, blood cancers and genetic diseases. The Company’s C100 program targets HSCs, immune cells, and disease-causing cells, the C200 program targets HSCs and disease-causing cells and the C300 program targets only immune cells. This is achieved by tuning the antibodies to specific cellular markers or receptors that are expressed on the particular cell types.

Price
Delayed
$17.60
Day's Change
-0.23 (-1.29%)
Bid
--
Ask
--
B/A Size
--
Day's High
17.99
Day's Low
16.95
Volume
(Light)

Today's volume of 180,434 shares is on pace to be much lighter than MGTA's 10-day average volume of 396,664 shares.

180,434

Activision stock falls 8% after earnings miss

4:24 pm ET November 8, 2018 (MarketWatch)
Print

Activision Blizzard Inc. (ATVI) shares dove in after-hours trading Thursday following an earnings report that missed expectations for the bottom line. The videogame publisher reported profit of $160 million, or 34 cents a share, on revenue of $1.51 billion, down from $1.62 billion a year ago. After adjustments, Activision reported earnings of 42 cents a share, up from 37 cents a share a year ago but still lower than analyst estimates. Analysts on average expected Activision to report adjusted earnings of 50 cents a share on net bookings of $1.66 billion. Activision reported net bookings -- which adds in other sales -- of $1.66 billion, down from $1.9 billion a year ago. After closing with a 3.5% decline at $62.79, shares were trading for less than $58 in extended trading after the report was released. The stock has already declined 24.5% so far this quarter, while the S&P 500 index has lost 3.4%.

-Jeremy C. Owens; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

November 08, 2018 16:24 ET (21:24 GMT)

Copyright (c) 2018 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.